enital TTP (cTTP), and c.84GA p.(Trp28), a attainable novel mutation linked to cTTP. Genetic analysis within the parents confirmed our patient as compound heterozygous. Treatment was switched to 2-weekly fresh frozen plasma administration. Right now, no relapse occurred and interval of infusion is extended to a 3-weekly routine. Conclusions: In conclusion, we suggest that pregnant girls presenting with TTP must be screened for inherited TTP, even while in the absence of the history of TTP-like signs and symptoms. Our practical experience demonstrates that very good clinical responses is often obtained with caplacizumab in cTTP.PB0850|Delayed Diagnosis of ETB Antagonist Source Congenital Thrombotic Thrombocytopenic Purpura Presenting as Recurrent Cryptogenic Strokes M. Desancho; M. Beltrami Moreira Weill Cornell Medicine/New York Presbyterian Hospital, New york, United StatesPB0849|TTP during Pregnancy: Acquired or Late- Onset Congenital A Diagnostic Challenge S. Demeester; N. De Beule; C. Orlando; A. De Becker; K. Jochmans Universitair Ziekenhuis Brussel, Brussels, Belgium Background: Thrombotic thrombocytopenic purpura (TTP) is often a unusual thrombotic microangiopathy, characterised by thrombocytopenia, haemolytic anemia and achievable organ injury. The disorder is brought about by a severely diminished action of von Willebrand factorcleaving protease ADAMTS13. That is on account of the presence of an inhibitory autoantibody while in the acquired type or to mutations in the ADAMTS13 gene within the uncommon inherited kind. Aims: In July 2020, a 20 weeks pregnant 31-year-old woman presented with common discomfort. Approaches: Laboratory investigations had been suggestive for TTP with serious thrombocytopenia and haemolytic anemia with presence of schistocytes. Success: ADAMTS13 activity was 3 , confirming TTP. Treatment method with everyday plasma exchange (PEX), caplacizumab and corticosteroids Background: Congenital Thrombotic Trombocytopenic Purpura (cTTP) Is actually a Unusual Disorder Triggered by ADAMTS13 Deficiency and Constitutes a Uncommon Reason behind Strokes Aims: To identify cTTP inside the differential diagnosis of cryptogenic stroke.ABSTRACT629 of|Approaches: TABLE 1 Hematologic and imaging results2001 Hemoglobin 11.76 mg/ dL Platelet count (15050 x103 cells/ L) Protein C action (7030 ) Protein S exercise (6263 ) Protein S Ag free (7060 ) ADAMTS13 action Imaging scientific studies MRI: previous left parietal, left caudate, and right frontal (subcortical/ parasagittal) infarcts MRI: acute infarction inside the ideal superior frontal gyrus and subacute infarct in the appropriate inferior frontal gyrus with hemorrhagic conversion Enoxaparin to allow for testing protein C and S Warfarin INR one.eight on admission 2002 Cathepsin K Inhibitor Source twelve.five 2006 twelve.eight April 2020 twelve.8 August 2020 11.five February 2021 twelve.14258 89172 14938 436055 60 five ; 9 after four plasma exchangesMRI:SubacuteCT: Acute proper middle cerebral infarctleft basal ganglia infarct and acute left parietal lobe infarct Ordinary transesophageal echocardiogramAntithrombotic agent Aspirin low-doseWarfarin INR target 2Apixaban 5 mg twice dailyApixaban five mg twice dailyOtherPlasma exchangePlasma infusions bi-monthlyCase report A 58-year-old female was referred to Hematology in August 2020 Results: following developing lingual bleeding and thrombocytopenia (38,000 cells/mm3). She had suffered a stroke at age 39, a transient ischemic assault at age forty and one more stroke at age 57. She was diagnosed with mild protein S deficiency and managed with warfarin. Her 2nd stroke occurred immediately after she had viral signs and symptoms, but SARS-CoV-2 RT-PCR was damaging. On admission her INR was subtherape